



EVALUATION OF ANTIOXIDANT PROPERTY OF EMPAGLIFLOZIN– DPPH ASSAY AND NITRIC OXIDE SCAVENGING ACTIVITY (IN-VITRO METHOD)

Dr. M.Sindhuja

Department of Pharmacology, Sree Balaji Medical College & Hospital, Bharath University, Chrompet, Chennai, Tamil Nadu, India.

Dr N.S Muthiah

Department of Pharmacology, Sree Balaji Medical College & Hospital, Bharath University, Chrompet, Chennai, Tamil Nadu, India.

Dr. R. Rajeswari

Department of Biochemistry, Thanjavur Medical College, Thanjavur, Tamil nadu, India.

ABSTRACT

Background: Diabetes Mellitus is a group of metabolic disease with increasing prevalence recently. Although obesity and physical inactivity accounts for the major risk for type II Diabetes Mellitus, increased production of free radicals leading to oxidative stress may also contribute to the pathogenesis of type II Diabetes Mellitus. Hence it is important to discover a hypoglycemic drug that reduces oxidative stress in diabetic patients.

Aim and Objective: This study, was performed to evaluate the antioxidant efficacy of Empagliflozin with Ascorbic acid by DPPH assay and nitric oxide scavenging activity, an in-vitro method.

Results: This study show that Empagliflozin on comparison with Ascorbic acid has antioxidant property and can be effectively used for reducing oxidative stress in patients with Diabetes

KEYWORDS : Diabetes Mellitus, Nitric oxide scavenging activity, DPPH Assay, Empagliflozin, SGLT2 Inhibitors

INTRODUCTION

Oxidative stress occurs due to an imbalance between free radical generation and radical scavenging activity which may lead to an increased radical production or decreased activity of antioxidant defenses or both¹. Free radicals are molecules or ions with unpaired electrons, which readily react with other molecule to produce chemical reactions².

The excessive free radical produced damage the bases in nucleic acids, amino acid side chains in proteins and double bonds in unsaturated fatty acids, and leads to oxidative stress, which causes damage to the DNA, RNA, proteins and lipids resulting in an increased risk for cancer, cardiovascular disease and other disorders³. To prevent the consequences of oxidative stress, the body has a defense system of *antioxidants*.

Antioxidants are molecules which neutralize the free radical by eliminating its unpaired condition by either accepting or donating electron(s)⁴. The antioxidants exerts its effects through various ways: free radical oxidation reaction inhibitors, by inhibiting the formation of free lipid radicals, by disrupting the propagation of the auto oxidation chain reaction, as singlet oxygen quenchers, as metal chelators that convert metal pro-oxidants into stable products and pro-oxidative enzymes inhibitor⁵.

Diabetes is one of the major risk factor for cardiovascular disease with its micro and macro vascular complications resulting in Myocardial infarction, cerebrovascular disease, coronary artery disease leading to increased number of death in diabetes population⁶. When endothelial cells are exposed to hyperglycemia there is increased production of free radicals. Also there is increased metabolism of glucose through polyol (sorbitol) pathway which partly contributes to the generation of reactive oxygen species leading to micro and macrovascular dysfunction.

Empagliflozin:

Sodium-glucose co-transporter-2 (SGLT2) inhibitors - a new group of oral medications used for treating type II DM. SGLT2 inhibitors reduce the renal reabsorption of urinary glucose by inhibiting the SGLUT2 present in the proximal renal tubules thereby excreting the glucose in urine. The reduction in plasma glucose is independent of insulin secretion and insulin peripheral resistance⁷.

EXPERIMENTAL SECTION

Nitric Oxide Scavenging Activity:

1. Test sample: crude drug of Empagliflozin (25mg)
2. Reference antioxidant: Ascorbic acid
3. Solvent: sodium nitroprusside in phosphate buffer
4. Reagent: Griess reagent
5. Spectrophotometer

Procedure:

The crude drug extract was dissolved in distilled water for this quantification. Sodium Nitroprusside (5mM) in standard phosphate buffer saline (0.025M, pH 7.4) was incubated with 100 mg/ml of sample and tubes were incubated at 29°C for 3 hours. Control experiment without the test compounds but with equivalent amount of buffer was conducted in an identical manner. After 3 hours incubated samples were diluted with 1 ml of Griess reagent. The absorbance of the colour developed during diazotization of Nitrite with sulphanilamide and its subsequent coupling with Naphthyl ethylene diamine hydrochloride was observed at 550nm on spectrophotometer. Same procedure was done with ascorbic acid which was standard in comparison to sample.


Calculations:

$$\% \text{ inhibition} = \frac{\text{O.D. of control} - \text{O.D. of Test}}{\text{O.D. of control}} \times 100$$

DPPH ASSAY:

DPPH (1,1-diphenyl-2-picrylhydrazyl) is characterised as a stable free radical by virtue of the delocalisation of the spare electron over the molecule as a whole, so that the molecules do not dimerise, as would be the case with most other free radicals. The delocalisation also gives rise to the deep violet colour, characterised by an absorption band in ethanol solution centered at about 520 nm. When a solution of DPPH is mixed with that of a substance that can donate a hydrogen atom, then this gives rise to the reduced form with the loss of this violet colour⁸.

Representing the DPPH radical by Z and the donor molecule by AH, the primary reaction is:



where ZH is the reduced form and A is free radical produced in this first step. This latter radical will then undergo further reactions

which control the overall stoichiometry, that is, the number of molecules of DPPH reduced (decolorised) by one molecule of the reductant.

Chemicals:

1. 1,1 – diphenyl -2-picrylhydrazyl (DPPH)
2. Dimethylsilphoxide (DMSO)
3. BHT (standard)-1.6mg/ml in methanol
4. Samples desired concentration from 1 mg /ml –max of 5mg / ml (in/DMSO)

Procedure:

Aliquot 3.7 ml of absolute methanol in all test tubes and 3.8ml of absolute methanol was added to blank. Add 100µl of BHT to tube marked as standard and 100µl of respective samples to all other tubes marked as tests. 200µl of DPPH reagent was added to all the test tubes including blank. Incubate all test tubes at room temperature in dark condition for 30 minutes. The absorbance of all samples was read at 517nm.

S.NO	REAGENTS	BLANK	STANDARD	TEST
1	Methanol	3.8ml	3.7ml	3.7ml
2	BHT	-	100µl	-
3	Sample	-	-	100µl
4	DPPH	200µl	200µl	200µl

Incubation at dark for 30 minutes
O.D at 517 nm

CALCULATION:

% Antioxidant activity

$$= \frac{(\text{Absorbance at blank}) - (\text{Absorbance at test})}{(\text{Absorbance at blank})} \times 100$$

RESULTS AND DISCUSSION

Table 1: Comparison of percentage of inhibition of Empagliflozin with Ascorbic acid (standard)

S.NO.	NAME OF THE SAMPLE	INHIBITION %
1.	Empagliflozin (25mg)	79.43
2.	Standard (Ascorbic Acid)	98.5




Figure 1: Bar Chart Comparing Percentage of Inhibition of Empagliflozin with Ascorbic Acid

The nitrogen oxide scavenging activity was recorded in terms of percentage Inhibition. It was observed that Empagliflozin has shown 79.43% inhibition in nitrogen oxide scavenging activity (Table 1). The Results obtained were comparative to Ascorbic acid as standard. The antioxidant efficacy of empagliflozin is demonstrated in (Figure.1).

Table 2: The Antioxidant activity of given samples using DPPH Assay method.

S.NO	SAMPLE	Concentration (µg/ml)	O.D	DPPH activity (%)
1	Ascorbic Acid (Standard)	1000	0.110	86.56
2	Empagliflozin (25mg)	1000	0.228	72.16




Figure 2: Bar Chart Comparing DPPH Activity percentage of Empagliflozin with Ascorbic Acid

DPPH Assay shows the efficacy of Empagliflozin to reduce the oxidative stress (Table.2). Empagliflozin has 72.16% of DPPH % Activity in comparison with Ascorbic acid (86.56%) (Figure.2).

SGLT2 Inhibitors are the new group of drug in the management of diabetes. It acts by increasing the renal glucose threshold by inhibiting the SGLT2 present in proximal renal tubules and causes increased excretion of glucose in urine. Apart from its antidiabetic, antimicrobial, anticalorigenic activity, SGLT2 inhibitors shows potent antioxidant property^{9,10}.

CONCLUSION

This study shows that Empagliflozin is highly efficacious in reducing oxidative stress. Thus the inhibitors of sodium-glucose co transporters type 2 (SGLT2) also possess an additional antioxidant activity and can be used as a novel therapy for the management of type 2 diabetes mellitus.

ACKNOWLEDGEMENTS

My immense thanks to Sree Balaji Medical College for providing me with laboratory assistance in conducting my experiment and I would also like to express my gratitude to all my professors, Department of Pharmacology for their guidance and encouragement in executing my project.

REFERENCES

1. McCord, J.M. The evolution of free radicals and oxidative stress. Am. J. Med. 2000, 108, 652–659.
2. B. Halliwell, "Biochemistry of Oxidative Stress," Biochemical Society Transactions, Vol. 35, No. 5, 2007, pp. 1147–1150
3. Giles G, Jacob C. Reactive sulfur species: an emerging concept in oxidative stress. Biol. Chem. 2002; 383:375–88.
4. B. Halliwell and J. M. C. Gutteridge, "The Definition and Measurement of Antioxidants in Biological Systems," Free Radical Biology and Medicine, Vol. 18, No. 1, 1995, pp. 125–126.
5. Darmanyan, A.P., Gregory, D.D., Guo, Y., Jenks, W.S., Burel, L., Eloy, D., Jardon, P. 1998. Quenching of singlet oxygen by oxygen- and sulfur-centered radicals: Evidence for energy transfer to peroxy radicals in solution. J. Am. Chem. Soc. 120, 396–403.
6. American Diabetes Association: National Diabetes fact sheet: 2002.
7. Nauck MA. Update on developments with SGLT2 inhibitors in the management of type 2 diabetes. Drug Des Devel Ther. 2014; 8: 1335–1380.
8. Blois S. Antioxidant Determinations by the Use of a Stable Free Radical Nature 181, 1199–1200; 26 April 1958.
9. Rosenstock J, Jelaska A, Wang F, et al. Empagliflozin as add-on to basal insulin for 78 weeks improves glycemic control with weight loss in insulin-treated type 2 diabetes (T2DM) Can J Diabetes. 2013; 37:532.
10. Scheen A. Pharmacokinetic and pharmacodynamic profile of empagliflozin, a sodium glucose co-transporter 2 inhibitor. Clin Pharmacokinet. 2014; 53(3):213–225.